(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 March 2023 (30.03.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/049731 A2

(51) International Patent Classification:
A61K 31/52 (2006.01) *A61K 31/513* (2006.01)

(21) International Application Number:
PCT/US2022/076757

(22) International Filing Date:
21 September 2022 (21.09.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/246,547 21 September 2021 (21.09.2021) US

(71) Applicant: **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 2-9, Kanda Tsukasa-Machi, Chiyoda-ku, Tokyo, 101-8535 (US).

(72) Inventors; and

(71) Applicants: **KEER, Harold** [US/US]; 4420 Rosewood Drive, Suite 200, Pleasanton, California 94588 (US). **AZAB, Mohammad** [US/US]; 1160 Mission St, Unit 1206, San Francisco, California 94103 (US). **HAO, Yong** [CA/CA]; 6820 Fleming Street, Vancouver, BC V5P 3H5 (CA).

(74) Agent: **MYERS BIGEL, P.A.**; PO Box 37428, Raleigh, North Carolina 27627 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS OF TREATING MYELODYSPLASTIC SYNDROMES WITH DECITABINE AND CEDAZURIDINE

(57) Abstract: Provided herein are methods of treating myelodysplastic syndromes (MDS) in a subject in need thereof. Also provided herein are methods of treating lower-risk MDS and chronic myelomonocytic leukemia (CMML) in a subject in need thereof. Also provided herein are methods of treating lower-risk MDS and chronic myelomonocytic leukemia (CMML) in a subject having a *TP53* mutation in need thereof. Such methods include administering to the subject an effective amount of cedazuridine and an effective amount of decitabine, thereby treating the myelodysplastic syndrome. Such methods may increase the subject's survival (e.g., overall median survival) to about 130% to about 400% relative to survival obtained by treatment with a hypomethylating agent alone.




FIG. 1

[Continued on next page]

WO 2023/049731 A2

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*